Edotreotide
Pancreatic Neuroendocrine Tumor
Floatz Rating
B57/100
Confidence
Indicative
Sponsor
ITM Solucin GmbH
Modality
protein_peptide
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06441331CT.gov Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors | — | Recruiting | — | — | — |
NCT05568017CT.gov Neoadjuvant PRRT With Y-90-DOTATOC in pNET | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Neuroendocrine Tumor
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Edotreotide (this asset) | ITM Solucin GmbH | P2 | B · 57 |
| Oxodotreotide | University of Chicago | P4 | BBB |
| Everolimus | Exelixis | P4 | BBB |
| Irinotecan | M.D. Anderson Cancer Center | P2/3 | BB |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | RayzeBio, Inc. | P3 | BB |
| Capecitabine | Gustave Roussy, Cancer Campus, Grand Paris | P3 | BB |
| Fluorouracilum | H. Lee Moffitt Cancer Center and Research Institute | P2/3 | BB |
| Zanzalintinib | Exelixis | P3 | BB |
| Sapanisertib | National Cancer Institute (NCI) | P2 | B |
+41 more in the Pancreatic Neuroendocrine Tumor cohort
Other indications for Edotreotide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Digestive System Neuroendocrine Neoplasm | — | P3 | B · 63 |
| Neuroblastoma | — | P2 | B · 60 |
| Carcinoid Tumor | — | P2 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Edotreotide in Pancreatic Neuroendocrine Tumor. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/edotreotide-pancreatic-neuroendocrine-tumor
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →